FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078670327> ?p ?o ?g. }

• W2078670327 endingPage "177" @default.
• W2078670327 startingPage "173" @default.
• W2078670327 abstract "Objective To demonstrate the safety and immunogenicity of intradermal rabies pre-exposure prophylaxis with purified chick embryo cell vaccine (PCECV) in schoolchildren age 5 to 8 years in Thailand. Study design In a randomized, open-label, phase II clinical trial, 2 or 3 intradermal doses of 0.1 mL PCECV (Rabipur®) were administered to 703 schoolchildren on days 0 and 28 or on days 0, 7, and 28. In 206 children, 2 simulated post-exposure booster doses were given 1 year after the primary vaccination series. Rabies virus– neutralizing antibody (RVNA) titers were determined by the rapid fluorescent focus inhibition test. Results In school-age children in Thailand, a pre-exposure immunization regimen of 3 intradermal doses of PCECV produced adequate immune responses. After primary vaccination, all subjects developed RVNA titers ≥0.5 IU/mL and demonstrated a rapid increase in RVNA titer after 2 simulated post-exposure booster immunizations 1 year after the primary vaccination series. No serious adverse drug reactions occurred. Conclusions Rabies pre-exposure immunization with PCECV is safe and immunogenic, and its implementation could save the lives of many children in rabies-endemic areas. To demonstrate the safety and immunogenicity of intradermal rabies pre-exposure prophylaxis with purified chick embryo cell vaccine (PCECV) in schoolchildren age 5 to 8 years in Thailand. In a randomized, open-label, phase II clinical trial, 2 or 3 intradermal doses of 0.1 mL PCECV (Rabipur®) were administered to 703 schoolchildren on days 0 and 28 or on days 0, 7, and 28. In 206 children, 2 simulated post-exposure booster doses were given 1 year after the primary vaccination series. Rabies virus– neutralizing antibody (RVNA) titers were determined by the rapid fluorescent focus inhibition test. In school-age children in Thailand, a pre-exposure immunization regimen of 3 intradermal doses of PCECV produced adequate immune responses. After primary vaccination, all subjects developed RVNA titers ≥0.5 IU/mL and demonstrated a rapid increase in RVNA titer after 2 simulated post-exposure booster immunizations 1 year after the primary vaccination series. No serious adverse drug reactions occurred. Rabies pre-exposure immunization with PCECV is safe and immunogenic, and its implementation could save the lives of many children in rabies-endemic areas." @default.
• W2078670327 created "2016-06-24" @default.
• W2078670327 creator A5002370259 @default.
• W2078670327 creator A5011663838 @default.
• W2078670327 creator A5024092595 @default.
• W2078670327 creator A5043959015 @default.
• W2078670327 creator A5075389283 @default.
• W2078670327 creator A5080821337 @default.
• W2078670327 creator A5088346005 @default.
• W2078670327 date "2007-08-01" @default.
• W2078670327 modified "2023-09-27" @default.
• W2078670327 title "Pre-Exposure Rabies Vaccination Using Purified Chick Embryo Cell Rabies Vaccine Intradermally is Immunogenic and Safe" @default.
• W2078670327 cites W1970179868 @default.
• W2078670327 cites W1970191976 @default.
• W2078670327 cites W1994490224 @default.
• W2078670327 cites W2026443236 @default.
• W2078670327 cites W2048910808 @default.
• W2078670327 cites W2054775296 @default.
• W2078670327 cites W2057169935 @default.
• W2078670327 cites W2097191128 @default.
• W2078670327 cites W2117645097 @default.
• W2078670327 cites W2120506475 @default.
• W2078670327 cites W2120846322 @default.
• W2078670327 cites W2148194784 @default.
• W2078670327 doi "https://doi.org/10.1016/j.jpeds.2007.02.044" @default.
• W2078670327 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17643772" @default.
• W2078670327 hasPublicationYear "2007" @default.
• W2078670327 type Work @default.
• W2078670327 sameAs 2078670327 @default.
• W2078670327 citedByCount "50" @default.
• W2078670327 countsByYear W20786703272012 @default.
• W2078670327 countsByYear W20786703272013 @default.
• W2078670327 countsByYear W20786703272014 @default.
• W2078670327 countsByYear W20786703272015 @default.
• W2078670327 countsByYear W20786703272016 @default.
• W2078670327 countsByYear W20786703272017 @default.
• W2078670327 countsByYear W20786703272018 @default.
• W2078670327 countsByYear W20786703272019 @default.
• W2078670327 countsByYear W20786703272020 @default.
• W2078670327 countsByYear W20786703272021 @default.
• W2078670327 countsByYear W20786703272022 @default.
• W2078670327 countsByYear W20786703272023 @default.
• W2078670327 crossrefType "journal-article" @default.
• W2078670327 hasAuthorship W2078670327A5002370259 @default.
• W2078670327 hasAuthorship W2078670327A5011663838 @default.
• W2078670327 hasAuthorship W2078670327A5024092595 @default.
• W2078670327 hasAuthorship W2078670327A5043959015 @default.
• W2078670327 hasAuthorship W2078670327A5075389283 @default.
• W2078670327 hasAuthorship W2078670327A5080821337 @default.
• W2078670327 hasAuthorship W2078670327A5088346005 @default.
• W2078670327 hasConcept C109663412 @default.
• W2078670327 hasConcept C12590561 @default.
• W2078670327 hasConcept C126322002 @default.
• W2078670327 hasConcept C159047783 @default.
• W2078670327 hasConcept C159654299 @default.
• W2078670327 hasConcept C197934379 @default.
• W2078670327 hasConcept C203014093 @default.
• W2078670327 hasConcept C22070199 @default.
• W2078670327 hasConcept C2776849203 @default.
• W2078670327 hasConcept C2777961786 @default.
• W2078670327 hasConcept C2778283251 @default.
• W2078670327 hasConcept C2780674857 @default.
• W2078670327 hasConcept C2780801004 @default.
• W2078670327 hasConcept C2780868878 @default.
• W2078670327 hasConcept C2781413609 @default.
• W2078670327 hasConcept C32611913 @default.
• W2078670327 hasConcept C71924100 @default.
• W2078670327 hasConcept C8891405 @default.
• W2078670327 hasConceptScore W2078670327C109663412 @default.
• W2078670327 hasConceptScore W2078670327C12590561 @default.
• W2078670327 hasConceptScore W2078670327C126322002 @default.
• W2078670327 hasConceptScore W2078670327C159047783 @default.
• W2078670327 hasConceptScore W2078670327C159654299 @default.
• W2078670327 hasConceptScore W2078670327C197934379 @default.
• W2078670327 hasConceptScore W2078670327C203014093 @default.
• W2078670327 hasConceptScore W2078670327C22070199 @default.
• W2078670327 hasConceptScore W2078670327C2776849203 @default.
• W2078670327 hasConceptScore W2078670327C2777961786 @default.
• W2078670327 hasConceptScore W2078670327C2778283251 @default.
• W2078670327 hasConceptScore W2078670327C2780674857 @default.
• W2078670327 hasConceptScore W2078670327C2780801004 @default.
• W2078670327 hasConceptScore W2078670327C2780868878 @default.
• W2078670327 hasConceptScore W2078670327C2781413609 @default.
• W2078670327 hasConceptScore W2078670327C32611913 @default.
• W2078670327 hasConceptScore W2078670327C71924100 @default.
• W2078670327 hasConceptScore W2078670327C8891405 @default.
• W2078670327 hasIssue "2" @default.
• W2078670327 hasLocation W20786703271 @default.
• W2078670327 hasLocation W20786703272 @default.
• W2078670327 hasOpenAccess W2078670327 @default.
• W2078670327 hasPrimaryLocation W20786703271 @default.
• W2078670327 hasRelatedWork W1998519227 @default.
• W2078670327 hasRelatedWork W2038220108 @default.
• W2078670327 hasRelatedWork W2055360631 @default.
• W2078670327 hasRelatedWork W2055580608 @default.
• W2078670327 hasRelatedWork W2066760593 @default.
• W2078670327 hasRelatedWork W2416394895 @default.
• W2078670327 hasRelatedWork W2419237419 @default.

• next